Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma.

Khushman M, Patel GK, Laurini JA, Bhardwaj A, Roveda K, Donnell R, Sherling K, Case B, Frankel AE, Pai S, Taylor W, Tan MCB, Mizrahi M, Nelson C, Wyatt M, Patton M, McClellan S, Singh S, Wang B, Singh AP.

J Gastrointest Oncol. 2019 Aug;10(4):695-702. doi: 10.21037/jgo.2018.07.02.

2.

Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.

Zieman D, Frankel AE.

J Immunother. 2019 Oct;42(8):318-320. doi: 10.1097/CJI.0000000000000291.

PMID:
31318723
3.

The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.

Alkharabsheh O, Sidiqi MH, Aljama MA, Gertz MA, Frankel AE.

Acta Haematol. 2019 Jul 16:1-6. doi: 10.1159/000500976. [Epub ahead of print] Review.

4.

The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.

Maharjan AS, McMillin GA, Patel GK, Awan S, Taylor WR, Pai S, Frankel AE, Nelson C, Wang B, Hosein PJ, Singh AP, Khushman M.

Clin Colorectal Cancer. 2019 Sep;18(3):e280-e286. doi: 10.1016/j.clcc.2019.04.005. Epub 2019 May 3.

PMID:
31160238
5.

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota.

Frankel AE, Deshmukh S, Reddy A, Lightcap J, Hayes M, McClellan S, Singh S, Rabideau B, Glover TG, Roberts B, Koh AY.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419846379. doi: 10.1177/1534735419846379.

6.

Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies.

Alkharabsheh O, Frankel AE.

Biomedicines. 2019 Jan 5;7(1). pii: E6. doi: 10.3390/biomedicines7010006. Review.

7.

Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.

Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA.

Br J Cancer. 2018 Oct;119(8):928-936. doi: 10.1038/s41416-018-0278-4. Epub 2018 Oct 15.

PMID:
30318513
8.

Tumor endothelial marker 8 promotes cancer progression and metastasis.

Høye AM, Tolstrup SD, Horton ER, Nicolau M, Frost H, Woo JH, Mauldin JP, Frankel AE, Cox TR, Erler JT.

Oncotarget. 2018 Jul 10;9(53):30173-30188. doi: 10.18632/oncotarget.25734. eCollection 2018 Jul 10.

9.

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.

Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY.

Neoplasia. 2017 Oct;19(10):848-855. doi: 10.1016/j.neo.2017.08.004. Epub 2017 Sep 15.

10.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS.

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

11.

A STING-activating nanovaccine for cancer immunotherapy.

Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, Du M, Huang G, Wang C, Chen X, Porembka MR, Lea J, Frankel AE, Fu YX, Chen ZJ, Gao J.

Nat Nanotechnol. 2017 Jul;12(7):648-654. doi: 10.1038/nnano.2017.52. Epub 2017 Apr 24.

12.

Academic Cancer Center Phase I Program Development.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.

Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.

13.

Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.

Frankel AE, Eskiocak U, Gill JG, Yuan S, Ramesh V, Froehlich TW, Ahn C, Morrison SJ.

Neoplasia. 2017 Apr;19(4):255-260. doi: 10.1016/j.neo.2017.01.010. Epub 2017 Mar 6.

14.

Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells.

Thorburn J, Staskiewicz L, Goodall ML, Dimberg L, Frankel AE, Ford HL, Thorburn A.

Mol Pharmacol. 2017 Jan;91(1):58-64. Epub 2016 Nov 9.

15.

Blastic plasmacytoid dendritic cell neoplasm with t(11;19)(q23;p13.3);KMT2A(MLL) rearranged: a diagnostic challenge.

Gehlbach D, Koduru P, John G, Fuda F, Frankel AE, Chen W.

Br J Haematol. 2017 Jan;176(1):8. doi: 10.1111/bjh.14389. Epub 2016 Oct 24. No abstract available.

PMID:
27774582
16.

Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma.

Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Frankel AE, Johnson TM, DeBerardinis RJ, Morrison SJ.

Nat Commun. 2016 Sep 29;7:13080. doi: 10.1038/ncomms13080. No abstract available.

17.

Developing EZH2-Targeted Therapy for Lung Cancer.

Frankel AE, Liu X, Minna JD.

Cancer Discov. 2016 Sep;6(9):949-52. doi: 10.1158/2159-8290.CD-16-0800.

18.

Discharging dynamics in an electrolytic cell.

Feicht SE, Frankel AE, Khair AS.

Phys Rev E. 2016 Jul;94(1-1):012601. doi: 10.1103/PhysRevE.94.012601. Epub 2016 Jul 5.

PMID:
27575173
19.

Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).

Bekdash A, Darwish M, Timsah Z, Kassab E, Ghanem H, Najjar V, Ghosn M, Nasser S, El-Hajj H, Bazerbachi A, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ.

Transl Oncol. 2015 Oct;8(5):347-57. doi: 10.1016/j.tranon.2015.07.001.

20.

Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency.

Burrage LC, Sun Q, Elsea SH, Jiang MM, Nagamani SC, Frankel AE, Stone E, Alters SE, Johnson DE, Rowlinson SW, Georgiou G; Members of Urea Cycle Disorders Consortium, Lee BH.

Hum Mol Genet. 2015 Nov 15;24(22):6417-27. doi: 10.1093/hmg/ddv352. Epub 2015 Sep 10.

21.

Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.

Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM.

Haematologica. 2015 Jun;100(6):794-800. doi: 10.3324/haematol.2015.123711. Epub 2015 Mar 20.

22.

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA.

Clin Cancer Res. 2015 Mar 15;21(6):1267-72. doi: 10.1158/1078-0432.CCR-14-2877.

23.

Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells.

Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel AE, Abi-Habib RJ.

J Neurooncol. 2015 Mar;122(1):75-85. doi: 10.1007/s11060-014-1698-5. Epub 2015 Jan 8.

PMID:
25567351
24.

Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.

Rakheja D, Fuda F, Vandergriff T, Boriack R, Medeiros BC, Frankel AE, Chen W.

Hum Pathol. 2015 Feb;46(2):322-6. doi: 10.1016/j.humpath.2014.10.013. Epub 2014 Nov 4.

PMID:
25481493
25.

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F.

Haematologica. 2015 Feb;100(2):223-30. doi: 10.3324/haematol.2014.111740. Epub 2014 Nov 7.

26.

In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts.

Agrawal V, Woo JH, Mauldin JP, Stone EM, Meininger CJ, Jo C, Kleypas K, Frenkel EP, Frankel AE.

Melanoma Res. 2014 Dec;24(6):556-67. doi: 10.1097/CMR.0000000000000119.

PMID:
25304236
27.

Dynamics of a self-diffusiophoretic particle in shear flow.

Frankel AE, Khair AS.

Phys Rev E Stat Nonlin Soft Matter Phys. 2014 Jul;90(1):013030. Epub 2014 Jul 31.

PMID:
25122392
28.

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.

Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M.

Br J Haematol. 2014 Sep;166(6):862-74. doi: 10.1111/bjh.12978. Epub 2014 Jun 19.

29.

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E.

Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23.

30.

Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity.

Frankel AE.

Clin Pharmacol. 2013 Nov 26;5(Suppl 1):1-3. doi: 10.2147/CPAA.S55613. eCollection 2013. No abstract available.

31.

Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells.

Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE, Abi-Habib RJ.

Leuk Res. 2013 Nov;37(11):1565-71. doi: 10.1016/j.leukres.2013.08.007. Epub 2013 Aug 16.

PMID:
24018014
32.

Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.

Kassab E, Darwish M, Timsah Z, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ.

Transl Oncol. 2013 Feb;6(1):25-32. Epub 2013 Feb 1.

33.

Arginine deprivation therapy for malignant melanoma.

Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB.

Clin Pharmacol. 2013;5:11-9. doi: 10.2147/CPAA.S37350. Epub 2012 Dec 27.

34.

Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.

Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW.

Clin Cancer Res. 2013 Jan 1;19(1):148-57. doi: 10.1158/1078-0432.CCR-12-1258. Epub 2012 Nov 21.

35.
36.

Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.

Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE.

Protein Pept Lett. 2013 Apr;20(4):392-402. Review.

PMID:
23016580
37.

Toll-like receptor 4 knockout protects against anthrax lethal toxin-induced cardiac contractile dysfunction: role of autophagy.

Kandadi MR, Frankel AE, Ren J.

Br J Pharmacol. 2012 Oct;167(3):612-26. doi: 10.1111/j.1476-5381.2012.02040.x.

38.

Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics.

Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE, Liu JS.

Hybridoma (Larchmt). 2012 Apr;31(2):77-86. doi: 10.1089/hyb.2011.0100.

39.

Recombinant human arginase toxicity in mice is reduced by citrulline supplementation.

Mauldin JP, Zeinali I, Kleypas K, Woo JH, Blackwood RS, Jo CH, Stone EM, Georgiou G, Frankel AE.

Transl Oncol. 2012 Feb;5(1):26-31. Epub 2012 Feb 1.

40.

Targeting methionine auxotrophy in cancer: discovery & exploration.

Agrawal V, Alpini SE, Stone EM, Frenkel EP, Frankel AE.

Expert Opin Biol Ther. 2012 Jan;12(1):53-61. doi: 10.1517/14712598.2012.636349. Epub 2011 Nov 5. Review.

PMID:
22171665
41.

TEM8 targeted cancer therapy.

Frankel AE, Carter C, Kuo SR, Woo JH, Mauldin J, Liu JS.

Anticancer Agents Med Chem. 2011 Dec;11(10):983-92.

PMID:
22023048
42.

Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells.

Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, Frankel AE.

Anticancer Drugs. 2012 Jan;23(1):51-64. doi: 10.1097/CAD.0b013e32834ae42b.

PMID:
21955999
43.

The cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeleton.

Yang MY, Chaudhary A, Seaman S, Dunty J, Stevens J, Elzarrad MK, Frankel AE, St Croix B.

Biochim Biophys Acta. 2011 Jan;1813(1):39-49. doi: 10.1016/j.bbamcr.2010.11.013. Epub 2010 Dec 1.

44.

1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancer.

Vanderlaag K, Su Y, Frankel AE, Burghardt RC, Barhoumi R, Chadalapaka G, Jutooru I, Safe S.

BMC Cancer. 2010 Dec 3;10:669. doi: 10.1186/1471-2407-10-669.

45.

Computational and experimental investigations of mono-septanoside binding by Concanavalin A: correlation of ligand stereochemistry to enthalpies of binding.

Duff MR Jr, Fyvie WS, Markad SD, Frankel AE, Kumar CV, Gascón JA, Peczuh MW.

Org Biomol Chem. 2011 Jan 7;9(1):154-64. doi: 10.1039/c0ob00425a. Epub 2010 Nov 18.

PMID:
21085738
46.

Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism.

Kandadi MR, Hua Y, Ma H, Li Q, Kuo SR, Frankel AE, Ren J.

PLoS One. 2010 Oct 13;5(10):e13335. doi: 10.1371/journal.pone.0013335.

47.

14G2a anti-GD2 crossreactivity with the CD166 antigen.

Agrawal V, Frankel AE.

J Immunother. 2010 Nov-Dec;33(9):1014-5. doi: 10.1097/CJI.0b013e3181f3bf36. No abstract available.

PMID:
20948433
48.

Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.

Woo JH, Lee YJ, Neville DM, Frankel AE.

Methods Mol Biol. 2010;651:157-75. doi: 10.1007/978-1-60761-786-0_10.

PMID:
20686966
49.

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Vallera DA, Oh S, Chen H, Shu Y, Frankel AE.

Mol Cancer Ther. 2010 Jun;9(6):1872-83. doi: 10.1158/1535-7163.MCT-10-0203. Epub 2010 Jun 8.

50.

Supplemental Content

Loading ...
Support Center